UK – NICE OKs Xeljanz for individuals with juvenile idiopathic arthritis

The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xeljanz (tofacitinib) for the treatment of people with juvenile idiopathic arthritis in final draft guidance.

In its guidance, NICE has recommended Xeljanz for as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people aged two years and older.

The therapy is also available for young people whose arthritis has not responded adequately to disease-modifying antirheumatic drugs (DMARDs) if a tumour necrosis factor (TNF)-alpha inhibitor is not suitable or inadequately controls their condition, or the if Pfizer provides Xeljanz according to the commercial arrangement…